Kun for helsepersonell

Søk 

Menu

Close

Logg innLogg ut
LegemiddelTerapiområdeUtforsk merUtforsk merMateriellVideo/podkastNyhetsbrevKontakt oss
OmAlopecia AreataLITFULO virkningsmekanismeSALT EvalueringEffektALLEGRO-2b/3 studieoversiktHårrespons i hodebunnenPasientrapporterte utfallØyenbryn og vipperesponsFør og etter bilderSikkerhetALLEGRO-2b/3 bivirkningerSamlede sikkerhetsdataYtterligere sikkerhetsinformasjonKom i gangDoseringScreening og oppfølgingSette pasientmålPasientprofilerOpplæringsmateriellMateriellVideo
Alopecia Areata An autoimmune disease that causes inflammation at the hair follicle1‐3
  • Loss of hair follicle immune privilege leads to infiltration of the immune system, such as CD8+ cells, T cells, and NK cells, into and around the hair bulb in a pattern referred to as the swarm of bees4
  • Inflammatory cytokines are released during the activation and proliferation of immune cells, contributing to a cycle of sustained inflammation and follicle dystrophy that results in hair loss4-6
  • Activation of the JAK3 and the TEC kinase family of enzymes may be involved in the inflammatory response, resulting in hair loss in alopecia areata6‐8
For patients with alopecia areata, there remains a need for more treatment options9
  • Patients with 50% or more scalp hair loss have low spontaneous remission rates (~5%)10
  • Up to 36.1% of patients with alopecia areata are at risk of developing alopecia totalis or alopecia universalis10‐12
  • Alopecia areata can occur at any age and affects both children and adults10,13
  • Loss of eyebrows and/or eyelashes due to alopecia areata may result in eye irritation13
 Learn how LITFULO works LITFULO virkningsmekanismeLoadingCD8+=cluster of differentiation 8 positive; JAK=Janus kinase; NK=natural killer; TEC=tyrosine kinase expressed in hepatocellular carcinoma.ReferencesReferences:1. Islam N, Leung PSC, Huntley AC, et al. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015,14(2):81-89. doi:10.1016/j.autrev.2014.10.014 2. Gilhar A, Schrum AG, Etzioni A, et al. Alopecia areata: animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies. Autoimmun Rev. 2016;15(7):726-735. 3. Suchonwanit P, Kositkuljorn C, Pomsoong C. Alopecia areata: an autoimmune disease of multiple players. Immunotargets Ther. 2021;10:299-312. 4. Ito T. Recent advances in the pathogenesis of autoimmune hair loss disease alopecia areata. Clin Dev Immunol. 2013;2013:348546. doi:10.1155/2013/348546 5. Divito SJ, Kupper TS. Inhibiting Janus kinases to treat alopecia areata. Nat Med. 2014;20(9):989-990. doi:10.1038/nm.3685 6. Passeron T, King B, Seneschal J, Steinhoff M, et al. Inhibition of T-cell activity in alopecia areata: recent developments and new directions. Front Immunol. 2023;14:1243556. doi:10.3389/fimmu.2023.1243556 7. Xu H, Jesson MI, Seneviratne Ul, et al. PF-06651600, a dual JAK3/TEC family kinase inhibitor. ACS Chem Biol. 2019;14(6);1235-1242. doi:10.1021/acschembio.9b00188 8. Schwartzberg PL, Finkelstein LD, Readinger JA. TEC-family kinases: regulators of T-helper-cell differentiation. Nat Rev Immunol. 2005;5(4):284-295. doi:10.1038/nri1591 9. Guttman-Yassky E, Pavel AB, Diaz A, et al. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J Allergy Clin Immunol. 2022;149(4):1318-1328. doi:10.1016/j.jaci.2021.10.036 10. Tosti A, Bellavista S, lorizzo M. Alopecia areata: a long term follow-up study of 191 patients. J Am Acad Dermatol. 2006;55(3):438-441. doi:10.1016/j.jaad.2006.05.008 11. Gip L, Lodin A, Modin L. Alopecia areata: a follow-up investigation of outpatient material. Acta Derm Venereol. 1969;49(2):180-188. 12. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ 3rd. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1995;70(7):628-633. doi:10.4065/70.7.628 13. Wyrwich KW, Kitchen H, Knight S, et al. Development of clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) measures for eyebrow, eyelash and nail assessment in alopecia areata. Am J Clin Dermatol. 2020;21(5):725-732. doi:10.1007/s40257-020-00545-9Om See how LITFULO helped patients with severe alopecia areata EffektLoading Get appropriate patients started on LITFULO today Kom i gangLoading
PP-LGF-NOR-0019 | Utarbeidet 08.2024

Pfizer AS, Org.nr 915 213 596

Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo

Tlf.: +47 67 52 61 00


PP-BCP-NOR-0001 juni 2023

Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.

 




 
Du forlater nå PfizerPro.no
Nettstedet du kommer til er hverken eid eller kontrollert av Pfizer i Norge. Pfizer i Norge er ikke ansvarlig for innholdet på nettstedet du kommer til.
Kun for helsepersonell

Dette nettstedet er kun for helsepersonell.

Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.

Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.

Ja Nei